Lower profit in the Life Sciences Business due to engineer hiring, training and permit-related costs
First written in FY2018-Q1. 1 of 34 entries say "Advanced", first in 2026-05-11. Latest entry: 2026-08-10.
No other company in this theme has enough history to compare yet.
- FY2026Full-year revenue and profit growth in the Life Sciences BusinessAnnual report
「As a result, revenue from the Life Science business was ¥1,947.7 million, up 1.3% year on year, and segment profit was ¥355.2 million, up 27.1%.」
Revenue and profit increased as medical equipment maintenance and consulting services grew, the company won high-margin projects, and personnel allocation was optimized. - 2026-05-11AdvancedEarnings
「Maintenance services for medical equipment and consulting services grew. Profitability improved as we secured high-margin projects and optimized personnel allocation, resulting in higher revenue and profit year on year.」
The Life Sciences business posted higher revenue and profit as project wins and personnel allocation optimization improved profitability. - FY2026-H1Life Science business: first-half revenue and profit growthAnnual report
「As a result, revenue from the Life Science business for the six-month interim period was ¥970.7 million, up 11.3% year on year, and segment profit was ¥180.8 million, up 58.9%.」
Growth in maintenance and ICT services resulted in higher first-half revenue and profit for the Life Science business. - FY2025Full-year revenue and profit growth in the Life Sciences BusinessAnnual report
「As a result, revenue from the Life Science business was ¥1,922.3 million, up 8.7% year on year, and segment profit was ¥279.4 million, up 4.6%.」
Although maintenance and consulting services declined, ICT services for companies in the life science field grew, resulting in full-year revenue and profit growth. - FY2025-H1Life Science business: first-half revenue and profit growthAnnual report
「As a result, revenue from the Life Science business for the six-month interim period was ¥872.3 million, up 4.5% year on year, and segment profit was ¥113.8 million, up 10.7%.」
Although maintenance services declined, ICT and consulting services in the life science field, which the company is prioritizing, grew, resulting in higher first-half revenue and profit. - FY2024Life Science business full-year performance after the reorganizationAnnual report
「As a result, revenue from the Life Science business for the fiscal year was ¥1,769.2 million, and segment profit was ¥267.0 million.」
Following the reorganization, the Life Science business recorded revenue of ¥1,769.2 million and segment profit of ¥267.0 million, while focusing on expanding its ICT business in the life science field despite the loss of the boost from large spot projects. - FY2024-Q3Life Science business performance for the first nine months after the reorganizationAnnual report
「Revenue from the Life Science business for the first nine months of the fiscal year was ¥1,287.8 million, and segment profit was ¥177.0 million.」
Following the reorganization of the reportable segments, the Life Science business recorded revenue of ¥1,287.8 million and segment profit of ¥177.0 million for the first nine months. - FY2024-Q2Life Science business performance in the first half after the reorganizationAnnual report
「Revenue from the Life Science business for the first six months of the fiscal year was ¥834.9 million, and segment profit was ¥102.8 million.」
Following the reorganization of the reportable segments, the Life Science business recorded revenue of ¥834.9 million and segment profit of ¥102.8 million for the first six months. - FY2024-Q1Life Science business performance in the first quarter after the reorganizationAnnual report
「Revenue from the Life Science business for the first quarter of the fiscal year was ¥425.6 million, and segment profit was ¥58.4 million.」
The Life Science business recorded revenue of ¥425.6 million and segment profit of ¥58.4 million. - FY2023Full-year revenue and profit growth in the Life Sciences BusinessAnnual report
「As a result, revenue from the Life Science Services business for the fiscal year was ¥1,548.8 million, up 11.5% year on year, and segment profit was ¥253.9 million, up 62.6%.」
The Life Science Services business posted sharp revenue and profit growth as it continued to win orders for spot projects involving medical equipment. - FY2023-Q3Cumulative third-quarter revenue and profit growth in the life sciences businessAnnual report
「During the first nine months of the fiscal year, revenue and profit increased year on year because the company continued to win orders for spot projects involving medical equipment. As a result, revenue from the Life Science Services business for the first nine months of the fiscal year was ¥1,167.3 million, up 29.9% year on year, and segment profit was ¥202.5 million, up 133.2%.」
The Life Science Services business posted sharp revenue and profit growth by continuing to win orders for spot projects involving medical equipment. - FY2023-Q2First-half revenue and profit growth in the life sciences businessAnnual report
「During the first six months of the fiscal year, revenue and profit increased year on year because the company continued to win orders for spot projects. As a result, revenue from the Life Science Services business for the first six months of the fiscal year was ¥742.9 million, up 39.9% year on year, and segment profit was ¥111.7 million, up 123.9%.」
Revenue and segment profit increased as the Life Science Services business continued to win orders for spot projects, with segment profit up 123.9% year on year. - FY2023-Q1Life Science Services business: first-quarter revenue and profit growthAnnual report
「During the first quarter of the fiscal year, revenue and profit increased year on year because the company continued to win orders for spot projects. As a result, revenue from the Life Science Services business for the first quarter of the fiscal year was ¥393.4 million, up 58.4% year on year, and segment profit was ¥64.3 million, up 258.1%.」
The Life Science Services business posted sharp revenue and profit growth as it continued to win orders for spot projects. - FY2022Life Science Services business: full-year revenue and profit growthAnnual report
「As a result, revenue from the Life Science Services business for the fiscal year was ¥1,389.6 million, up 40.3% year on year, and segment profit was ¥156.1 million, up 54.0%.」
The business posted full-year revenue and profit growth as maintenance services for medical and chemical analysis equipment recovered and the medical ICT business expanded. - FY2022-Q3Cumulative third-quarter revenue and profit growth in the life sciences businessAnnual report
「As a result, revenue from the Life Science Services business for the first nine months of the fiscal year was ¥898.4 million, up 25.3% year on year, and segment profit was ¥86.9 million, up 54.2%.」
Revenue and profit increased as maintenance services recovered following the lifting of entry restrictions at hospitals and pharmaceutical companies, and spot projects related to medical equipment and analytical equipment performed well. - FY2022-Q2First-half revenue and profit growth in the life sciences businessAnnual report
「As a result, revenue from the Life Science Services business for the first six months of the fiscal year was ¥531.2 million, up 15.2% year on year, and segment profit was ¥49.9 million, up 119.0%.」
Maintenance services for medical equipment and chemical analysis equipment recovered following the lifting of entry restrictions at hospitals and pharmaceutical companies, while spot projects also performed well, resulting in higher revenue and profit. - FY2022-Q1Life Science business: first-quarter revenue growth and return to profitabilityAnnual report
「During the first quarter of the fiscal year, revenue and profit increased year on year as maintenance services for medical equipment and chemical analysis equipment manufacturers recovered following the lifting of entry restrictions at hospitals and pharmaceutical companies. As a result, revenue from the Life Science Services business for the first quarter of the fiscal year was ¥248.3 million, up 19.7% year on year, while segment profit was ¥18.0 million, compared with a segment loss of ¥6.5 million in the same period of the previous year.」
Maintenance services recovered following the lifting of entry restrictions at hospitals and pharmaceutical companies, allowing the Life Science Services business to increase revenue and return to profitability from the loss recorded in the same period of the previous year. - FY2021-Q3Life Science business: nine-month revenue growth, profit decline and utilization recoveryAnnual report
「During the first nine months of the fiscal year, the scope of operations expanded compared with the same period of the previous year. However, many service recipients were hospitals and research facilities in eastern Japan, and visits to these facilities were not possible from April to June 2020 because of measures to prevent COVID-19 infections. As a result, services such as inspections and repairs of medical equipment and chemical analysis equipment could not be performed as scheduled. This reduced engineer utilization and profit margins. To address the decline, the company implemented measures to downsize its operating structure, including reducing the number of engineers. Engineer utilization recovered from July 2020 onward. As a result, revenue from the Life Science Services business for the first nine months of the fiscal year was ¥710.3 million, up 6.6% year on year, while segment profit was ¥64.6 million, down 8.1%.」
Revenue increased as the scope of operations expanded, while profit declined because restrictions on visits reduced utilization and the company implemented measures to downsize its operating structure. The company stated that engineer utilization had recovered since July 2020. - FY2021-Q2Life Science business: first-half revenue growth, profit decline and downsizingAnnual report
「During the first six months of the fiscal year, the scope of operations expanded compared with the same period of the previous year. However, many service recipients were hospitals and research facilities in eastern Japan, and visits to these facilities were not possible from April to June because of measures to prevent COVID-19 infections. As a result, services such as inspections and repairs of medical equipment and chemical analysis equipment could not be performed as scheduled. This reduced engineer utilization and profit margins. To address the decline, the company implemented measures to downsize its operating structure, including reducing the number of engineers. Engineer utilization recovered from July onward. As a result, revenue from the Life Science Services business for the first six months of the fiscal year was ¥460.9 million, up 9.6% year on year, while segment profit was ¥34.9 million, down 9.4%.」
Revenue increased as the scope of operations expanded, but profit declined because restrictions on visits reduced utilization. The company implemented measures to downsize its operating structure, including reducing the number of engineers. Utilization has recovered since July. - FY2021-Q1Life Science business: first-quarter revenue growth and sharp profit declineAnnual report
「As a result, revenue from the Life Science Services business for the first quarter of the fiscal year was ¥207.3 million, up 4.8% year on year, while segment profit was ¥0.3 million, down 97.6%.」
Although the scope of operations expanded, inspections, repairs and other services could not be performed as scheduled because visits to hospitals and research facilities were restricted, resulting in lower engineer utilization and profit margins. - FY2020Full-year revenue and profit growth in the Life Sciences BusinessAnnual report
「As a result, revenue from the Life Science Services business for the fiscal year was ¥939.1 million, up 23.2% year on year, and segment profit was ¥111.8 million, up 36.4%.」
The Life Science Services business posted full-year revenue and profit growth, driven by contracted maintenance services for chemical analysis equipment manufacturers and support for LIMS implementation. - FY2020-Q3Cumulative third-quarter revenue and profit growth in the life sciences businessAnnual report
「The company newly secured contracts for maintenance services from a manufacturer of chemical analysis equipment and implementation support services for a laboratory information management system (LIMS) using IT. As a result, revenue from the life sciences services business for the cumulative third quarter was ¥666.322 million, up 18.7% year on year, and segment profit was ¥70.374 million, up 16.2%.」
The life sciences services business posted higher revenue and profit after newly securing contracts for maintenance services from a chemical analysis equipment manufacturer and LIMS implementation support services. - FY2020-Q2First-half revenue and profit growth in the life sciences businessAnnual report
「Market demand in the medical device field is expanding due to digitalization, and the number of projects accepted increased as a result of active sales efforts. As a result, revenue from the life sciences services business for the cumulative second quarter was ¥420.526 million, up 19.8% year on year, and segment profit was ¥38.481 million, up 59.3%.」
The number of projects accepted in the medical device field increased as a result of sales efforts, resulting in higher revenue and profit for the life sciences services business in the first half. - FY2020-Q1First-quarter revenue growth and return to profitability in the life sciences businessAnnual report
「Market demand in the medical device field is expanding due to digitalization, and the number of projects accepted increased as a result of active sales efforts. As a result, revenue from the life sciences services business for the cumulative first quarter was ¥197.736 million, up 24.4% year on year, and segment profit was ¥14.563 million, compared with a segment loss of ¥231 thousand in the same period of the previous year.」
The number of projects accepted in the medical device field increased as a result of sales efforts, and the life sciences services business posted higher revenue and moved from a loss in the same period of the previous year to segment profit. - FY2019Full-year revenue growth and profit decline in the life sciences businessAnnual report
「Revenue from the life sciences services business for the fiscal year was ¥753.026 million, up 7.7% year on year. In terms of profit, segment profit was ¥90.978 million, down 17.7%, due to upfront investments including engineer hiring and training to support further business expansion.」
Although the life sciences services business posted higher revenue due to spot projects and other work, profit declined due to upfront investments including engineer hiring and training. - FY2019-Q3Cumulative third-quarter revenue growth and profit decline in the life sciences businessAnnual report
「During the cumulative third quarter, revenue increased as a result of expanding the office area and hiring and training additional engineers. In addition, the increase in contracted short-term life sciences services projects contributed to revenue of ¥555.281 million, up 11.2% year on year, while segment profit was ¥68.529 million, down 4.6%.」
Although revenue increased due to office expansion, engineer hiring and training, and an increase in contracted short-term projects, segment profit declined year on year. - FY2019-Q2First-half revenue growth and profit decline in the life sciences businessAnnual report
「During the cumulative second quarter, revenue increased as a result of expanding the office area and hiring and training additional engineers. As a result, revenue was ¥346.236 million, up 4.9% year on year, while segment profit was ¥29.239 million, down 42.6%.」
Although revenue increased due to office expansion and engineer hiring and training, profit in the life sciences business declined substantially in the first half. - FY2019-Q1Quarterly revenue growth and profit decline in the life sciences businessAnnual report
「During the cumulative first quarter, revenue increased as a result of expanding the office area and hiring and training additional engineers. However, these investment costs could not be offset, resulting in revenue of ¥156.811 million, up 7.4% year on year, and segment profit of ¥2.227 million, down 86.6%.」
Although revenue in the life sciences business increased due to office expansion and engineer hiring and training, profit declined substantially as the investment costs could not be offset. - FY2018Full-year revenue growth and profit decline in the life sciences businessAnnual report
「As a result, revenue from the life sciences services business for the fiscal year was ¥699.302 million, up 11.4% year on year, while segment profit was ¥110.559 million, down 0.6%.」
Although revenue increased due to the acceptance of analytical instrument systems projects and other work, profit declined slightly due to investments including engineer hiring and training and medical device licensing costs. - FY2018-Q3Cumulative third-quarter revenue growth and profit decline in the life sciences businessAnnual report
「As a result, revenue was ¥499.515 million, up 8.1% year on year, while segment profit was ¥71.830 million, down 8.0%, as the volume of work increased year on year.」
Although revenue increased due to the acceptance of analytical instrument systems projects and other work, profit declined due to investments including engineer hiring and training and medical device licensing costs. - FY2018-Q2First-half revenue growth and profit decline in the life sciences businessAnnual report
「During the cumulative second quarter, the acceptance of an analytical instrument systems project boosted revenue and profit. However, in response to demand from existing customers, overseas medical device manufacturers, to expand their operations and to acquire new customers, the company needed to hire and train additional engineers. It therefore actively hired and trained engineers, including through the use of partners, while temporarily reducing existing engineers' utilization rates for product training, which reduced the volume of contracted existing work. In addition, expenses were recorded to obtain licenses for the manufacture and marketing of medical devices. As a result, revenue was ¥330.174 million, up 8.2% year on year, while segment profit was ¥50.930 million, down 2.3%.」
Although revenue increased due to the acceptance of analytical instrument projects and other work, profit in the life sciences business declined due to engineer hiring and training, product training, and licensing costs. - FY2018-Q1First statedAnnual report
「The volume of contracted existing work declined as engineers were hired mid-career and existing engineers temporarily reduced their utilization rates to undergo product training. In addition, expenses were recorded to obtain licenses for the manufacture and marketing of medical devices. As a result, revenue was ¥145.986 million, down 4.6% year on year, while segment profit was ¥16.645 million, down 45.6%.」
The life sciences services business posted lower revenue and profit due to hiring and training to support business expansion with new and existing customers and costs to obtain medical device licenses.